FCGR3B and neoplasm: Patients homozygous for the higher-affinity CD16A variant with follicular lymphoma (FL) (75), non-Hodgkin lymphoma (76), CRC (77), or breast cancer (78) have a better clinical outcome after treatment with anti-tumor mAbs than patients with the low-affinity CD16 allele (see Table 2).